Tim Crowder

Name: Tim Crowder

Email:  ztcc11@goldmail.etsu.edu

Hometown City/Country:  Bristol, TN

Undergraduate Degree/Institution: BS/East Tennessee State University

Graduate Degree/Institution: MS/George Washington University

Graduate program:  Doctor of Public Health, Epidemiology

Year of Entry:  Fall 2008

Research Advisor: Dr. Toni Bounds

Research Interests: Cancer

ClinicaL Trial Experiences

Protocol 2008XXXX:  A Randomized Open-Label Study to Evaluate the Safety and Efficacy of XXXXX and Ibandronate in Postmenopausal Women Sub-Toptimally Treated with Daily or Weekly Biphospates.

Protocol 2008XXXX:  A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated with Immune (Idiopathic). Thrombocytopenia Purpura (ITP)

Protocol 2007XXXX:  A Phase 2 Randomized, Doublic-Blind, Placebo controlled, parallel group, fixed dose study of AMGXXX in subjects with chronic kidney disease on hemodialysis with hyperphospatemia

Protocol 2006XXXX:  A Randomized, Double-Blind, Placeb0-Controlled, Multi-Center Phase 3 Study of XXXX, As Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-Care)

Protocol 2006XXXX:  A Randomized, Double-Blind, Multi-Center Phase 2 Study, to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG XXX or Placebo in Subjects with Metastatic Clear Cell Carcinoma of the Kidney

Protocol 2006XXXX:  A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination with AMG XXX in Subjects with Advanced Recurrent Epithelial Ovarian or Paritoneal Cancer.

Protocol 2006XXXX:  A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of AMG XXX or Placebo in Combination with Gemcitabine as First-Line Therapy for Metastatic Adenocarcinoma of the Pancreas.

Protocol 2006XXXX:  Multi-Center, Open-Label, Randomized, Phas 2 Clinical Trial Evaluating Safety and Efficacy of  FOLFIRI with Either XXXXXX or Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer

Protocol 2006XXXX:  Multi-center, Open-Label Single Arm Trial Evaluating  XXXXXX in Combination with FOLFIRI Therapy Following First-line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal     Cancer

Protocol 2006XXXX:  Phase 2, Single Arm, Open-Label, Multi-Center Trial of Second-Line XXXXXX Monotherapy in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Protocol 2006XXXX:  A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG XXX Treatment of Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide

Protocol 2006XXXX:  A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Phase II Study to Determine the Safety and Efficacy of AMG XXX in Subjects with Moderate to Severe Asthma


Hypertension Regional Site Manager, Crowder Clinical Consulting, 2011-Present

Johnson City, TN Oncology Regional Site Manager, Amgen Inc., Thousand Oaks, California, 2005-2011

Clinical Research Associate, World Wide Clinical Trials, Atlanta, Georgia, 2000-2005

Clinical Research Associate, CTMS, Inc, Bristol, Tennessee, 1998-2000

QA Microbiologist, Laure Beverage Company, Johnson City, Tennessee, 1997-1998

Microbiology Laboratory Technician, Baxter Healthcare Corporation, Johnson City, Tennessee, 1994-1997


OSHA Hazardous Waste Operations and Emergency Response Certification, 2011

American Association of Clinical Research Professionals Certification, 2000

direct edit